As the final quarter of 2025 comes into view, the calendar is filling with important scientific gatherings that will shape the next wave of urology practice and research. Among these, the European Society for Medical Oncology (ESMO) Congress has become one …

At the American Society of Clinical Oncology (ASCO) Annual Meeting 2025, held from 31 May to 3 June in Chicago, Illinois, updated efficacy and safety data from the randomised, double-blind, placebo-controlled Phase III AMPLITUDE (NCT04497844) clinical …

Johnson & Johnson (NYSE: JNJ) today announced results for first-quarter 2025. “The power of Johnson & Johnson’s uniquely diversified portfolio was on full display this quarter, with strong operational sales growth reinforcing our confidence in 2025 …

Johnson & Johnson (NYSE: JNJ) today announced results for fourth-quarter and full year 2024. "2024 was a transformative year for Johnson & Johnson, marked by strong growth, an accelerating pipeline and industry-leading investments in …

By ALEX BRUMMER, CONSULTANT EDITOR Updated: 16:50 EDT, 19 September 2025 Here is a bizarre outcome from Donald Trump's State Visit: Britain's leading-edge big pharma companies AstraZeneca and GSK are pledging £59billion of investment in the US over …

Johnson & Johnson (NYSE: JNJ) today announced results for third-quarter 2024. “Johnson & Johnson’s strong results in the third quarter reflect the unique breadth of our business and commitment to delivering the next wave of healthcare innovation,” …

Johnson & Johnson (NYSE: JNJ) today announced results for second-quarter 2024. “Johnson & Johnson's second quarter performance reflects our relentless focus on advancing the next wave of medical innovation and resulted in strong sales and …

Darolutamide (Nubeqa) is an androgen receptor inhibitor that, when combined with androgen-deprivation therapy (ADT), has demonstrated significant efficacy in treating metastatic hormone-sensitive prostate cancer (mHSPC). Tian Zhang, MD, MHS, an associate …

New Brunswick: Johnson & Johnson has announced that William N. (Bill) Hait, M.D., Ph.D., will retire from his position as Executive Vice President, Chief External Innovation and Medical Officer, in September of this year. Since joining Johnson & …

Breaking News Innovative Medicine sales were up 1%, while COVID-19 Vaccine sales were down 97%. 05.20.24 Johnson & Johnson 1Q Revenues: $21.4 billion (+2%) 1Q Earnings: $5.4 billion (loss of $491 million 1Q23) Comments: Innovative Medicine sales were …